EGFR and non-small cell lung carcinoma: In another study, Chen et al. identified a novel hederagenin−NO donor hybrid, which suppresses the proliferation of gefitinib-resistant H1975 (IC50 = 8.1 μM) and osimertinib-resistant H1975-LTC (IC50 = 7.6 μM) non-small-cell lung cancer cells via the inhibition of EGFR-LTC kinase (IC50 = 0.01 μM), a mutant EGFR kinase [43].